Alumis (ALMS) Competitors $4.13 -0.01 (-0.24%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.16 +0.04 (+0.85%) As of 08/1/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. QURE, SION, SNDX, DNA, CRMD, ANAB, VIR, XERS, CRON, and IMTXShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include uniQure (QURE), Sionna Therapeutics (SION), Syndax Pharmaceuticals (SNDX), Ginkgo Bioworks (DNA), CorMedix (CRMD), AnaptysBio (ANAB), Vir Biotechnology (VIR), Xeris Biopharma (XERS), Cronos Group (CRON), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors uniQure Sionna Therapeutics Syndax Pharmaceuticals Ginkgo Bioworks CorMedix AnaptysBio Vir Biotechnology Xeris Biopharma Cronos Group Immatics Alumis (NASDAQ:ALMS) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Do analysts rate ALMS or QURE? Alumis presently has a consensus target price of $19.80, suggesting a potential upside of 379.42%. uniQure has a consensus target price of $36.55, suggesting a potential upside of 166.95%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alumis is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91 Which has more volatility and risk, ALMS or QURE? Alumis has a beta of -1.5, meaning that its stock price is 250% less volatile than the S&P 500. Comparatively, uniQure has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ALMS or QURE? 78.8% of uniQure shares are held by institutional investors. 40.7% of Alumis shares are held by company insiders. Comparatively, 4.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ALMS or QURE? In the previous week, uniQure had 21 more articles in the media than Alumis. MarketBeat recorded 24 mentions for uniQure and 3 mentions for Alumis. Alumis' average media sentiment score of 0.29 beat uniQure's score of 0.24 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is ALMS or QURE more profitable? Alumis has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. Alumis' return on equity of -406.27% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -406.27% -107.29% uniQure -1,387.98%-1,010.74%-33.27% Which has stronger earnings & valuation, ALMS or QURE? uniQure has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/AuniQure$27.12M27.70-$239.56M-$3.92-3.49 SummaryuniQure beats Alumis on 7 of the 13 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$225.24M$2.99B$5.47B$9.53BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.7428.8923.83Price / SalesN/A178.71371.4466.13Price / CashN/A41.9535.4557.96Price / Book0.758.508.265.54Net Income-$294.23M-$55.06M$3.25B$259.28M7 Day Performance6.44%-3.99%-3.73%-4.66%1 Month Performance25.91%9.58%4.28%4.40%1 Year Performance-68.18%6.70%25.85%17.92% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis2.9453 of 5 stars$4.13-0.2%$19.80+379.4%-67.5%$225.24MN/A0.00N/AQUREuniQure2.4226 of 5 stars$15.210.0%$37.82+148.7%+83.0%$832.60M$20.20M-3.46500Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSIONSionna TherapeuticsN/A$18.74-2.1%$38.50+105.4%N/A$826.88MN/A0.0035Positive NewsLockup ExpirationSNDXSyndax Pharmaceuticals3.5568 of 5 stars$9.56-4.3%$34.10+256.6%-54.6%$826.48M$43.72M-2.49110Upcoming EarningsDNAGinkgo Bioworks1.1761 of 5 stars$14.03-5.9%$8.50-39.4%N/A$820.47M$227.04M-1.53640News CoverageGap UpCRMDCorMedix2.7538 of 5 stars$11.59+0.7%$17.14+48.0%+161.0%$791.46M$43.47M53.0530News CoveragePositive NewsANABAnaptysBio2.2031 of 5 stars$26.93-0.2%$47.13+75.0%-27.6%$791.06M$111.87M-5.55100News CoverageUpcoming EarningsVIRVir Biotechnology2.8746 of 5 stars$5.71-1.0%$30.25+430.2%-48.3%$790.04M$74.21M-1.35580News CoverageUpcoming EarningsShort Interest ↑XERSXeris Biopharma3.4832 of 5 stars$5.03-2.8%$6.25+24.4%+121.4%$785.84M$222.55M-16.75290News CoveragePositive NewsUpcoming EarningsShort Interest ↑CRONCronos Group2.5755 of 5 stars$2.04-1.7%N/A-17.0%$784.86M$117.61M15.66450News CoverageUpcoming EarningsIMTXImmatics2.1585 of 5 stars$6.44-0.2%$14.67+127.7%-45.1%$784.00M$168.65M-37.94260 Related Companies and Tools Related Companies QURE Alternatives SION Alternatives SNDX Alternatives DNA Alternatives CRMD Alternatives ANAB Alternatives VIR Alternatives XERS Alternatives CRON Alternatives IMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
